News Releases

RARE Disease Innovators, Investors, Industry Partners, and Patient Groups to Catalyze Partnerships in Union Square

Interactive Area to Provide Exciting Insights into the Future of Lighting in IoT

- Kisqali plus an oral endocrine partner demonstrated significant efficacy with sustained benefit of nearly two years (median PFS 23.8 vs 13.0 months for endocrine therapy alone) and an early response with separation of the PFS curves as early as eight weeks[1]

Foundation welcomes dozens of new members and more than 4,000 attendees to Austin for annual North American event